Virtu Financial LLC Purchases 13,632 Shares of Neurocrine Biosciences, Inc. $NBIX

Virtu Financial LLC grew its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 775.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,389 shares of the company’s stock after purchasing an additional 13,632 shares during the quarter. Virtu Financial LLC’s holdings in Neurocrine Biosciences were worth $2,183,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Wick Capital Partners LLC bought a new position in Neurocrine Biosciences during the fourth quarter valued at approximately $1,142,000. Invesco Ltd. lifted its holdings in shares of Neurocrine Biosciences by 6.1% in the 4th quarter. Invesco Ltd. now owns 343,421 shares of the company’s stock worth $48,707,000 after acquiring an additional 19,810 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in shares of Neurocrine Biosciences by 82.1% in the 4th quarter. Corient Private Wealth LLC now owns 7,292 shares of the company’s stock worth $1,034,000 after acquiring an additional 3,287 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of Neurocrine Biosciences by 29.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 40,957 shares of the company’s stock valued at $5,809,000 after purchasing an additional 9,355 shares in the last quarter. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at $418,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $158.29 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $169.57. The stock has a market cap of $15.92 billion, a price-to-earnings ratio of 24.39, a PEG ratio of 1.19 and a beta of 0.40. The stock’s 50 day simple moving average is $148.53 and its two-hundred day simple moving average is $140.84.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Jude Onyia sold 11,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $160.25, for a total transaction of $1,762,750.00. Following the completion of the sale, the insider owned 25,846 shares of the company’s stock, valued at $4,141,821.50. This trade represents a 29.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 1,250 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $168.06, for a total value of $210,075.00. Following the completion of the transaction, the director owned 2,838 shares of the company’s stock, valued at $476,954.28. This represents a 30.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 355,234 shares of company stock worth $55,330,060 in the last 90 days. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Sanford C. Bernstein started coverage on shares of Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $185.00 price target on shares of Neurocrine Biosciences in a research report on Monday, April 6th. HC Wainwright raised their price objective on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. Zacks Research upgraded Neurocrine Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 15th. Finally, Weiss Ratings raised Neurocrine Biosciences from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $187.52.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.